"10.1371_journal.pone.0141618","plos one","2015-11-06T00:00:00Z","Kerrilyn Naidoo; Sibusiso T Malindisa; Tyrone C Otgaar; Martin Bernert; Bianca Da Costa Dias; Eloise Ferreira; Uwe Reusch; Stefan Knackmuss; Melvyn Little; Stefan F T Weiss; Boitelo T Letsolo","School of Molecular and Cell Biology, University of the Witwatersrand, Private Bag 3, Wits, 2050, Johannesburg, Republic of South Africa; Affimed GmbH, Technologiepark, Im Neuenheimer Feld 582, 69120, Heidelberg, Germany","Conceived and designed the experiments: BTL SFTW. Performed the experiments: KN BDCD STM TCO MB. Analyzed the data: KN BDCD STM TCO MB EF. Contributed reagents/materials/analysis tools: UR SK ML. Wrote the paper: KN STM MB TCO BDCD BTL SFTW.","S.F.T.W. is currently a PLOS ONE Editorial Board Member. The patent, EP1670826, co-owned by the University of the Witwatersrand and Affimed Therapeutics AG covers LRP/LR specific antibodies used in this study as tools for diagnosis and therapy of cancer. This granted European patent was validated in the United Kingdom, France, Germany, Switzerland and Austria. Further, a South African Provisional Patent Application 2014/08860, owned by the University of the Witwatersrand covers the inhibition of the development of cancer cells by the modification of the levels of LRP/LR. This does not alter the authorsâ€™ adherence to all the PLOS ONE policies on sharing data and materials. U.R., S.K. and M.L. are affiliated with or employed by Affimed Therapeutics AG, a commercial company which produces therapeutic antibodies for the treatment of cancer and inflammatory diseases. This does not alter our adherence to PLOS ONE policies on sharing data and materials.","2015","11","Kerrilyn Naidoo","KN",11,TRUE,2,5,6,7,TRUE,TRUE,FALSE,0,NA,FALSE
